BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28857419)

  • 1. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.
    Ou YJ; Chiu HF; Wong YH; Yang CC; Yang YH
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1286-1295. PubMed ID: 28857419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
    Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
    Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis.
    Peng R; Liang X; Zhang G; Yao Y; Chen Z; Pan X; Wang J; Liu G
    Biomed Res Int; 2020; 2020():5606573. PubMed ID: 33102580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
    Oh YH; Yoon C; Park SM
    World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies.
    Ou YJ; Chiu HF; Wong YH; Yang YH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1107-1115. PubMed ID: 27501339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
    Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
    J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of atypical femoral fracture during and after bisphosphonate use.
    Schilcher J; Koeppen V; Aspenberg P; Michaƫlsson K
    Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
    Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
    J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.
    Sun K; Liu JM; Sun HX; Lu N; Ning G
    Osteoporos Int; 2013 Jan; 24(1):279-86. PubMed ID: 23052941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate for fracture prevention in postmenopause.
    Holder KK; Kerley SS
    Am Fam Physician; 2008 Sep; 78(5):579-81. PubMed ID: 18788232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension and breast cancer risk: a systematic review and meta-analysis.
    Han H; Guo W; Shi W; Yu Y; Zhang Y; Ye X; He J
    Sci Rep; 2017 Mar; 7():44877. PubMed ID: 28317900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study.
    Bae YS; Chang J; Park SM
    Arch Osteoporos; 2019 Mar; 14(1):41. PubMed ID: 30888545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bisphosphonates and risk of breast cancer.
    Vestergaard P; Fischer L; Mele M; Mosekilde L; Christiansen P
    Calcif Tissue Int; 2011 Apr; 88(4):255-62. PubMed ID: 21253712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonate use associated with a decreased risk of breast cancer.
    Dreyfuss JH
    CA Cancer J Clin; 2010; 60(6):343-4. PubMed ID: 20959402
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.
    Xiao Y; Xia J; Li L; Ke Y; Cheng J; Xie Y; Chu W; Cheung P; Kim JH; Colditz GA; Tamimi RM; Su X
    Breast Cancer Res; 2019 Jan; 21(1):16. PubMed ID: 30696460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.
    Bonovas S; Nikolopoulos G; Bagos P
    Br J Clin Pharmacol; 2013 Sep; 76(3):329-37. PubMed ID: 23594375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.